Managing Venous Thromboembolism in Latin American Patients: Emerging Results from the Brazilian Registry

Jackson S. Caiafa; Marcos de Bastos; L. K. Moura; S. Raymundo

doi:10.1055/s-2002-34076

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2002; 28(s3): 047-050
DOI: 10.1055/s-2002-34076

Managing Venous Thromboembolism in Latin American Patients: Emerging Results from the Brazilian Registry

Jackson S. Caiafa¹ , Marcos de Bastos² , L. K. Moura³ , S. Raymundo⁴

¹Hospital Naval Marcílio Dias, Rio de Janeiro, Brazil
²Hospital Geral da Instituto de Previdência, Belo Horizonte, Brazil
³Departamento de Cirurgia Vascular, Hospital São Rafael, Salvador, Brazil
⁴Departamento de Angiologia e Cirurgia Vascular, Hospital Austa, S.J. Rio Preto, Brazil

Abstract

ABSTRACT

A Brazilian National Registry was established in 1999 to investigate the incidence of risk factors for venous thromboembolism (VTE) in hospitalized medical and surgical patients and to investigate the use of thromboprophylaxis in these populations. A 4-year pilot study confirmed the feasibility and value of a registry project in this region, showing a dramatic increase in the use of low-molecular-weight heparin (LMWH) over the study period, associated with a sixfold reduction in the incidence of symptomatic VTE. Data on more than 27,000 patients from the Brazilian Registry have revealed that almost 25% of high-risk patients and 45% of those at moderate risk currently receive no thromboprophylaxis. Among the high-risk patients-in whom general measures alone are not considered appropriate prophylaxis-42% of patients did not receive pharmacological prophylaxis with either LMWH or unfractionated heparin. The Brazilian Registry highlights the need to raise awareness of VTE risk factors and recommended prophylactic regimens in Latin America.

KEYWORDS

Low-molecular-weight heparin - risk evaluation - surgical patients - thromboprophylaxis - venous thromboembolism

Full Text

References

REFERENCES

1 National Institute of Health Consensus Development Conference Statement. Prevention of thrombosis and pulmonary embolism. NIH Consensus Development JAMA 1986 256: 744-749
2 Nicolaides A N, Arcelus J, Belcaro G. Prevention of venous thromboembolism. European Consensus Statement, November 1-5, 1991, developed at Oakley Court Hotel, Windsor, United Kingdom. Int Angiol . 1992; 11 151-159
3 Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J . 1992; 305 567-574
4 Clagett G P, Anderson Jr A F, Heit J. Prevention of venous thromboembolism. Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest . 1995; 108(Suppl) 312S-328S
5 Caprini J A, Arcelus J I, Hasty J H. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost . 1991; 17(Suppl 3) 304-312
6 Haas S. Impact of the European Consensus Statement on the acceptance of low molecular weight heparin. Clin Appl Thromb Hemost . 1996; 2(Suppl 1) S35-S39
7 International Consensus Statement (guidelines according to scientific evidence). Prevention of venous thromboembolism Int Angiol 1997 16: 3-38